Investor Relations


Overview
Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease, or PAD. The company manufactures and sells a suite of products including the Lightbox imaging console, as well as the Wildcat, Kittycat2, Ocelot family of catheters, and Pantheris. Avinger is based in Redwood City, California.
Stock QuoteMore
AVGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorC
Price$4.60
Change (%) Stock is Down 0.18 (3.77%)
Volume88,746
Data as of 09/28/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore
DateTitle 
09/13/16Avinger Signs Agreement with U.S. Department of Veterans Affairs for Lumivascular Technology
REDWOOD CITY, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced the company has received an FSS Contract Award from the U.S. Department of Veterans Affairs (VA) which establishes terms under which VA hospitals across the country may acquire Avinger’s portfolio of Optical Coherence Tomography (OCT) image-guided catheters for their veterans hospitals. VA operates the nation's larges... 
Printer Friendly Version
09/07/16Avinger Signs Agreement with HealthTrust for Lumivascular Technology
REDWOOD CITY, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced it has signed an agreement with HealthTrust. The agreement establishes terms under which members of the HealthTrust group purchasing organization may acquire Avinger’s portfolio of technologies designed to treat PAD, including Avinger’s PantherisTM Optical Coherence Tomography (OCT) image-guided atherectomy system, which... 
Printer Friendly Version
08/16/16Avinger, Inc. Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
REDWOOD CITY, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’s common stock at a price to the public of $3.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,285,800 shares of Avinger’s common stock. The tota... 
Printer Friendly Version
08/11/16Avinger, Inc. Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the pricing of its public offering of 8,572,000 shares of its common stock at a price to the public of $3.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,285,800 additional shares of its common stock. The Company expects to close the offerin... 
Printer Friendly Version
08/10/16Avinger, Inc. Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that it intends to offer, subject to market and other conditions, newly issued shares of common stock, $0.001 par value (the "Offering" with such shares being the "Shares") in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange ... 
Printer Friendly Version
08/09/16Avinger, Inc. Announces Participation in Canaccord Genuity 36th Annual Growth Conference
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company plans to participate in the Canaccord Genuity 36th Annual Growth Conference in Boston. Avinger management is scheduled to present on Wednesday, August 10, 2016 at 1:00pm ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s websit... 
Printer Friendly Version
08/01/16Avinger, Inc. Announces Second Quarter 2016 Results
REDWOOD CITY, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the second quarter ended June 30, 2016. Second Quarter Highlights Revenue of $4.7 million, a 54% increase compared to the second quarter of 2015 Added 19 lumivascular accounts, the most in a single quarter, expanding the installed base of the Company's lumivascular platform to... 
Printer Friendly Version
07/25/16Avinger, Inc. to Announce Second Quarter 2016 Results on Monday, August 1, 2016
Conference call scheduled for Monday, August 1, 2016 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2016 after the close of trading on Monday, August 1, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interes... 
Printer Friendly Version
07/12/16Avinger, Inc. Announces Preliminary Second Quarter 2016 Revenue Results
Management to host conference call today at 2:00pm PT/5:00pm ET REDWOOD CITY, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that based on preliminary unaudited financial results, it expects total revenue of approximately $4.7 million for the second quarter ended June 30, 2016, an increase of 57% from the second quarter of 2015.   Revenues from disposable devices were $... 
Printer Friendly Version
06/27/16Highmark Health’s VITAL Program to Evaluate Avinger’s Novel Treatment for Peripheral Artery Disease
Innovative Program Studies Full Impact of New Health Technologies PITTSBURGH and REDWOOD CITY, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Highmark Health, Allegheny Health Network (AHN) and Avinger, Inc. (NASDAQ:AVGR) announced a collaboration today to evaluate Pantheris™, Avinger’s novel image-guided atherectomy device for the treatment of peripheral artery disease (PAD). The partnership is part of Highmark Health’s VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovati... 
Printer Friendly Version
Upcoming EventsMore
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Avinger Inc posts new information to the site. Just enter your email address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Find a physician near you
Use the form below to find a physician in your area
Distance
Find a sales professional
Use the form below to find a sales professional in your area
Distance
Subscribe
Enter your email to sign up for updates and notifications